New combo therapy for bile duct cancer: what are the side effects?

NCT ID NCT05835778

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated May 15, 2026 · Updated 20 times

Summary

This study looked at side effects of the drug IMFINZI when given together with standard chemotherapy (gemcitabine and cisplatin) to people with advanced bile duct cancer that cannot be removed by surgery. A total of 236 patients took part. The main goal was to track any unwanted reactions. The study is now complete.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Aichi, Japan
Research Site

Aomori, Japan
Research Site

Chiba, Japan
Research Site

Ehime, Japan
Research Site

Fukushima, Japan
Research Site

Hokkaido, Japan
Research Site

Hyōgo, Japan
Research Site

Kagawa, Japan
Research Site

Kanagawa, Japan
Research Site

Kyoto, Japan
Research Site

Miyagi, Japan
Research Site

Nagano, Japan
Research Site

Nagasaki, Japan
Research Site

Nara, Japan
Research Site

Numakunai, Japan
Research Site

Okayama, Japan
Research Site

Osaka, Japan
Research Site

Saitama, Japan
Research Site

Shiga, Japan
Research Site

Shimane, Japan
Research Site

Shizuoka, Japan
Research Site

Tochigi, Japan
Research Site

Tokyo, Japan
Research Site

Yamaguchi, Japan

Conditions

Explore the condition pages connected to this study.

BILIARY TRACT CANCER